Table 1.

Clinical characteristics of the study population

Total N of patients	66
Age, median (range), years	65 (27-87)
Follow-up, median (95% CI), months	39 (27-87)
Gender, n (%)
Female	19 (29%)
Male	47 (71%)
Stage, n (%)
II	7 (11%)
III	46 (70%)
IV	13 (20%)
Melanoma subtype, n (%)
Cutaneous	51 (77%)
Mucosal	5 (8%)
Acral	4 (6%)
Unknown primary	6 (9%)
Primary site, n (%)
Trunk	17 (26%)
Extremities	24 (36%)
Head and neck	17 (26%)
Lymph nodes (unknown primary)	5 (8%)
Genital	1 (1.5%)
GI	1 (1.5%)
Other	1 (1.5%)
BRAF, n (%)
Mutated	28 (42%)
Wild-type	38 (58%)
NRAS, n (%)
Mutated	16 (24%)
Wild-type	50 (76%)
Neoadjuvant systemic therapy, n (%)
None	59 (89%)
Immunotherapy	3 (5%)
Targeted therapy	3 (5%)
Unknown (clinical trial)	1 (1.5%)
Adjuvant systemic therapy, n (%)
None	14 (21%)
Immunotherapy	41 (62%)
Targeted therapy	8 (12%)
Unknown (clinical trial)	3 (5%)
Adjuvant radiation, n (%)
Yes	15 (23%)
No	51 (77%)
Progressive disease, n (%)
Yes	22 (33%)
No	44 (67%)

CI, confidence interval; GI, gastrointestinal.